Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Kodiak Sciences Inc. (NASDAQ:KOD) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $31.1429.

Several research firms have recently commented on KOD. HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. Finally, UBS Group assumed coverage on shares of Kodiak Sciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock.

Institutional Trading of Kodiak Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its holdings in Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $29,000. Headlands Technologies LLC increased its holdings in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences in the 4th quarter valued at $72,000. Finally, Strs Ohio acquired a new position in shares of Kodiak Sciences in the 4th quarter valued at $87,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: GLOW2 Phase 3 topline showed Zenkuda superiority vs. sham, with 62.5% of treated patients achieving a ≥2‑step DRSS improvement vs. 3.3% for sham—supporting efficacy across two Phase 3 studies and setting up a likely BLA submission. Kodiak Sciences Announces Positive Topline Results in GLOW2
• Positive Sentiment: Major news outlets and financial press reported the successful late‑stage readout, triggering broad market buying and coverage that is amplifying investor interest. Reuters: Kodiak Sciences shares surge after eye drug succeeds in late-stage study
• Positive Sentiment: Industry press expects a Biologics License Application (BLA) filing next after the two positive Phase 3 studies, which would move Zenkuda toward regulatory review and potential commercialization. Bioworld: Kodiak’s Zenkuda sparkles in Glow2, BLA filing next
• Neutral Sentiment: Financial outlets and market movers lists highlighted KOD among the biggest gainers after the readout; this increases visibility but also invites short‑term trading and coverage-driven volatility. Seeking Alpha: Kodiak posts trial win
• Neutral Sentiment: Unusual options activity was reported—3,472 put options traded (a ~1,256% increase versus typical daily put volume)—which could reflect hedging by longs or speculative bets and may add intraday implied‑volatility pressure. (No direct article linked)
• Negative Sentiment: After a large one‑day rally the stock is potentially vulnerable to profit‑taking and heightened volatility; KOD has a high beta and a wide gap between current price and longer‑term moving averages, so technical pullbacks are possible.

Kodiak Sciences Trading Up 74.8%

Shares of NASDAQ:KOD opened at $39.76 on Friday. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $40.46. The company’s 50 day moving average is $24.95 and its 200 day moving average is $21.62. The company has a market cap of $2.11 billion, a PE ratio of -9.65 and a beta of 2.61.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.